Monday, February 19, 2018
 
 
Global Extremity Reconstruction Devices Market Is Expected To Reach US$ 16,663.2 Mn By 2025 - Credence Research
According to the latest market report published by Credence Research, Inc. “ 
HealthCombix, a Leading Blockchain Healthcare Platform, Partners with Y Combinator Alumnus NuCypher
NASHVILLE, Tenn., Feb. 18, 2018 /PRNewswire/ -- HealthCombix today announced that it has partnered with San Francisco based NuCypher to explore distributed security technology integrations to solve privacy, consent, and identity challenges in healthcare around the globe.
 



Cosmetic Dentist Wailuku Maui, HI Interviewed on Implant Dentistry

 
Cosmetic Dentist Pearl District, Downtown Portland OR, Interviewed on Dental Implants Solutions
Dr. Benjamin Wang, dentist from Centerport Dental in Downtown Portland, Pearl District, OR, recently interviewed on Doctor Relations, reveals that missing teeth are not...
 
Simple Steps Can Prevent Older Adults from Contracting the Flu

OMAHA, Neb. (PRWEB) February 18, 2018

 
Cosmetic Dentist Delray Beach, Boynton Beach, FL, Interviewed on Dental Implant Solutions
In a recent interview with Doctor Relations, Dr. Robert Adami, founder of Designer Family Dental in Delray Beach, Boynton Beach, FL, discussed that missing teeth aren't...
 
ImmVRse Collaborates With Imperial College to Lead Research on Impact of VR on Neural Activity
LONDON, Feb. 17, 2018 /PRNewswire/ -- The next frontier is truly the mind. To explore our vast galaxy, one of the most useful avenues has been Virtual Reality (VR). What makes VR so special is its ability to allow you to transport into another world without literally having to move an inch. That said, even though the body is .....
 
AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting
NORTH CHICAGO, Ill., Feb. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today presented new positive results from the pivotal Phase 3 ultIMMa-1 and ultIMMa-2 replicate clinical trials that evaluated the safety and efficacy of risankizumab (150 mg) compared to .....
 
AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
NORTH CHICAGO, Ill., Feb. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today presented new positive results from a Phase 2b dose-ranging study evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor,.....
 
Evolus Announces Presentation of Phase III European - Canadian Comparative Data
IRVINE, Calif., Feb. 17, 2018 /PRNewswire/ -- Evolus, Inc. (NASDAQ: EOLS) today announced the presentation of data from the Phase III comparative clinical trial of its investigational prabotulinumtoxinA 900 kilodalton (kDa) neuromodulator at the American Academy of Dermatology (AAD) meeting.
 
Warriors Empowered Through Winter Sports with Veterans' Charity
FLAGSTAFF, Ariz., Feb. 17, 2018 /PRNewswire-USNewswire/ -- Veterans gathered to bond and learn adaptive winter sports techniques from experienced instructors at the Arizona Snowbowl. During the two-day-adaptive ski and snowboard experience with Wounded Warrior Project® (WWP), some veterans with injuries opted for a.....
 


 
 
 
 
 
 
 
 
 
 
 
 
 





About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines